Allurion Revenue Drops 71 Percent in Q2
Allurion Technologies (NYSE:ALUR), a medical device company focused on non-surgical weight loss solutions, released its second quarter 2025 results on August 13, 2025. The headline was a sharp revenue drop to $3.4 million (GAAP) in Q2 2025, well below the $5.18 million GAAP consensus estimate and last year’s $11.8 million (GAAP) revenue. This shortfall reflected distribution partner changes, strategic pivots, and region-specific disruptions. Despite implementing aggressive cost controls that trimmed operating expenses by nearly half year-over-year, the company posted a $7.0 million operating loss, although that was an improvement from $9.3 million in Q2 2024. The quarter was marked by operational shifts, regulatory milestones, and management’s decision to withdraw forward guidance as it repositions for future growth.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.
Allurion Technologies develops medical devices and digital solutions for weight loss. Its flagship product is the Allurion Balloon, a swallowable gastric balloon designed to help patients lose weight without surgery or anesthesia. The company integrates this device with a mobile app and a connected scale, using artificial intelligence to guide patients through behavioral change and remote monitoring as part of the Allurion Program.
Source Fool.com
